Vixarelimab
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) receptor β subunit monoclonal antibody. Vixarelimab inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash[1].
Product Specifications
CAS Number
[2243320-83-2]
Product Name Alternative
KPL-716
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/vixarelimab.html
Purity
96.90
Solubility
10 mM in DMSO
Smiles
[Vixarelimab]
Molecular Weight
(145.042 kDa)
References & Citations
[1]Carl D Richards, et al. Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716. Acta Derm Venereol. 2020 Jul 2;100 (14) :adv00197.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1397147-01 0.5 mg (E-Coli)
Recombinant Human C-type lectin domain family 7 member A (CLEC7A), partial
Ask
View Details 
MBS1397147-02 0.05 mg (Baculovirus)
Recombinant Human C-type lectin domain family 7 member A (CLEC7A), partial
Ask
View Details MBS1397147-03 0.5 mg (Yeast)
Recombinant Human C-type lectin domain family 7 member A (CLEC7A), partial
Ask
View Details 
MBS1397147-04 0.05 mg (Mammalian-Cell)
Recombinant Human C-type lectin domain family 7 member A (CLEC7A), partial
Ask
View Details MBS1397147-05 1 mg (E-Coli)
Recombinant Human C-type lectin domain family 7 member A (CLEC7A), partial
Ask
View Details MBS1397147-06 0.1 mg (Baculovirus)
Recombinant Human C-type lectin domain family 7 member A (CLEC7A), partial
Ask
View Details